Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement

2026-03-16 10:52:47 ET

The last time I spoke about Abivax ( ABVX ) it was with a Seeking Alpha article entitled "Abivax: " Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026 ". With respect to this article, I mentioned that the company had already achieved positive results from its phase 3 ABTECT trials, which evaluated the use of mir-124 enhancer obefazimod for the treatment of patients with moderate-to-severe active ulcerative colitis [UC]. This would be positive 8-week induction trial data, where 50 mg of this drug in both the phase 3 ABTECT-1 and ABTECT-2 studies were able to achieve a placebo-adjusted remission rate of 19.3% and 13.4%, respectively. The last time I spoke about this company, it had a "Strong Buy" rating, and I believe that it is important to maintain this rating. Why is that? There are three major reasons why I'm keeping this rating on this stock. The first reason is because Abivax is still expected to release 44-week data from the phase 3 ABTECT-UC Maintenance study in late Q2 of 2026 [ Abivax Provides 2026 Corporate Outlook press release top headlines ]....

Read the full article on Seeking Alpha

For further details see: